Maestro TrayZ

See how Maestro TrayZ delivers real-time, reproducible data without sacrificing throughput. Explore our new application note to learn how label-free cytotoxicity and potency assays can support your workflow.

Immunotherapies such as CAR T cells that have shown success in treating liquid tumors have had limited efficacy against solid tumors, including glioblastoma. Natural killer (NK) cells represent a promising approach for solid tumor treatment, and understanding mechanisms of NK-mediated cytotoxicity is important for cell therapy development. In this application note, Axion Biosystems quantifies the kinetics of both antibody-dependent cellular cytotoxicity (ADCC) and CAR NK-mediated cytolysis against glioblastoma cells using the Maestro Z. Kinetics of these mechanisms are assessed across multiple target cell lines and effector:target ratios.

Trastuzumab promotes natural killer cell activation through antibody-dependent cellular cytotoxicity (ADCC). Understanding ADCC can help researchers develop immunotherapies with better targeting and efficacy. In this application note, Axion Biosystems examines and quantifies ADCC-specific killing using the monoclonal antibody trastuzumab and peripheral blood natural killer cells on the Maestro z. The ADCC response between donors and across multiple effector to target cell ratios is compared.

In this application note, Axion Biosystems uses the Maestro Z to develop a real-time, label-free potency assay for immune-cell mediated killing of 3D cancer spheroids.

Friday, March 20 at 15:00 GMT | 16:00 CET | 11:00 EDT | 08:00 PDT

Antibody-drug conjugates (ADCs) require precise, reliable in vitro assays to understand potency, kinetics, and mechanism of action early in development. Traditional endpoint assays often miss critical dynamic responses and introduce variability through dyes and labels.

In this 20‑minute SelectScience® TechTalk, Field Application Scientist Viswanath Lanka will demonstrate how the Maestro Z™ label‑free monitoring system enables real‑time, impedance‑based assessment of ADC‑mediated cytotoxicity. See how continuous kinetic data reveals differences in killing dynamics, accelerates detection, and supports confident potency quantification.

Register today to learn how to simplify your workflow, improve reproducibility, and apply practical examples of how Maestro Z supports confident decision-making in oncology drug discovery.

Key learning objectives:

• Understand why real-time, kinetic measurements are critical for accurately assessing ADC cytotoxicity
• Learn how label-free impedance assays can be faster and more sensitive than traditional endpoint methods
• Explore practical considerations for implementing real-time ADC assays in discovery workflows

Who should attend?

• Drug discovery, oncology, and ADC‑focused scientists across pharma, biotech, CROs, and academic labs working on targeted therapies, cytotoxicity, and phenotypic screening.
• Assay development, optimization, and cell‑based assay specialists, including lab managers and screening scientists running cytotoxicity, viability, and phenotypic workflows.
• Teams advancing antibody‑drug conjugates, oncology research, and next‑generation drug discovery, with a focus on stability, potency, and decision‑making in early development.

Certificate of attendance
If you attend the live TechTalk, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.

If you view the on-demand TechTalk, you can request a certificate of attendance by emailing editor@selectscience.net.

TechTalk details

• Cost: Free to attend
• Location: Online
• Duration: 20 minutes

Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on‑demand recording once it becomes available

In this video, Axion BioSystems introduces the Maestro TrayZ.